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Abstract
Background: Chronic hepatitis B (CHB) related morbidity and mortality can be reduced through risk group screening,
linkage to care and anti-viral treatment. This study estimates the number of CHB cases among foreign-born (migrants)
in the European Union and European Economic Area (EU/EEA) countries in order to identify the most affected
migrant populations.
Methods: The CHB burden was estimated by combining: demographic data on migrant population size by country
of birth in the EU/EEA, extracted from European statistical databases; and CHB prevalence in migrants’ countries of
birth and in EU/EEA countries, derived from a systematic literature search. The relative contribution of migrants from
endemic countries to the total CHB burden in each country was also estimated. The reliability of using country of birth
prevalence as a proxy for prevalence among migrants was assessed by comparing it to the prevalence found in studies
among migrants in Europe.
Results: An estimated 1–1.9 million CHB-infected migrants from endemic countries (prevalence ≥2%) reside in the EU/
EEA. Migrants from endemic countries comprise 10.3% of the total EU/EEA population but account for 25% (15%–35%)
of all CHB cases. Migrants born in China and Romania contribute the largest number of infections, with over 100,000
estimated CHB cases each, followed by migrants from Turkey, Albania and Russia, in descending order, with over 50,000
estimated CHB cases each. The CHB prevalence reported in studies among migrants in EU/EEA countries was lower than
the country of birth prevalence in 9 of 14 studies.
Conclusions: Migrants from endemic countries are disproportionately affected by CHB; their contribution however varies
between EU/EEA countries. Migrant focused screening strategies would be most effective in countries with a high relative
contribution of migrants and a low general population prevalence. In countries with a higher general population
prevalence and a lower relative contribution of migrants, screening specific birth cohorts may be a more effective use
of scarce resources. Quantifying the number of CHB infections among 50 different migrant groups residing in each of
the 31 EU/EEA host countries helps to identify the most affected migrant communities who would benefit from
targeted screening and linkage to care.
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Background
Migration flows in the first half of the twentieth century
were predominantly from Europe towards America.
Since the Second World War, economic and geopolitical
factors such as decolonisation, labour migration, the col-
lapse of communism, air travel, economic growth and
political crisis have changed this and migration to
Europe has increased [1]. Much of this migration has
been from low- and middle-income countries in Asia
and Africa, many of which have a high prevalence of
hepatitis B and C [2, 3]. Existing case-based surveillance
systems such as the European hepatitis B and C surveil-
lance system managed by the European Centre for Dis-
ease Prevention and Control are unable to accurately
quantify the number of chronic viral hepatitis cases
among migrants on account of different reporting, test-
ing and screening practices among member states. Add-
itional information sources and epidemiologic research
are needed to estimate the scale of chronic hepatitis B
virus infection in this population [4].
Hepatitis B virus (HBV) infection primarily affects the
liver. It usually has an insidious onset and can remain
undetected for many years. Up to 5% of HBV infections
in adults (up to 90% in young children) can progress to
become chronic and up to 30% of chronic cases may de-
velop liver cirrhosis [5].
Public health measures, including antenatal screening,
childhood HBV vaccination, stringent testing of blood
products, improved infection control practices and harm
reduction programmes, have led to a significant reduc-
tion of viral hepatitis transmission and a decline in the
number of acute HBV cases reported in many European
Union/European Economic Area (EU/EEA) countries
[6]. Limited or more recent implementation of these pri-
mary prevention measures explains the high prevalence
of viral hepatitis seen in many parts of the world, but es-
pecially in South East Asia, Sub-Saharan Africa and
Eastern Europe [7]. Vertical transmission from mother
to child and nosocomial transmission are considered to
be the main routes in intermediate (2–8%) and high
(>8%) HBsAg prevalence countries [5, 7].
Worldwide viral hepatitis related mortality in absolute
terms increased by 63% between 1990 and 2013, while
the associated disability adjusted life years increased by
34% during this time [8]. This global increase is largely
the result of inadequate prevention measures combined
with population growth in hepatitis endemic areas [8].
An estimated 13 to 14 million people in the WHO
European region are chronically infected with hepatitis B
[9, 10] and about 36,000 people die every year as a con-
sequence [9]. In Europe, chronic HBV infection is a
major cause of liver cirrhosis and 10–15% of hepatocel-
lular carcinoma (HCC), cases are attributed to chronic
hepatitis B (CHB) [10].
Antiviral treatment with nucleot(s)ides such as tenofo-
vir or entecavir can prevent the development of cirrhosis
and HCC and can suppress viral replication in a very
high proportion of cases [3]. However, because of the
largely asymptomatic nature of the infection until late
stages, it is estimated that between 40% and 80% of
people infected are unaware of their infection and many
are not diagnosed until after liver damage has occurred
[10, 11]. The population health benefits of effective
treatment can only be realised by improving early
detection of infection through targeted testing among
risk groups.
The WHO recently ratified the strategic goal to elim-
inate chronic viral hepatitis as a health threat in Europe
by 2030. The strategy and action plan published to
support countries and the region to achieve this goal
highlight ‘the who’ and ‘the where’ as the first two stra-
tegic pillars of elimination [12, 13]. Whilst it is suspected
that a large proportion of migrants to the EU come from
hepatitis B (HBsAg) intermediate (2%–8%) and high
(>8%) endemicity countries [2, 3], little is known about
the epidemiology of CHB among migrants. Specifically
lacking are robust estimates of the number of infections
among migrants and knowledge about which groups are
most affected. Estimates of which migrant groups are
most affected and would therefore benefit most from
(linguistically/culturally/specifically) targeted screening
programmes, early detection and treatment are required
if Europe is to achieve this ambitious elimination goal.
The aims of this study are: 1) to estimate the number
of CHB cases among the foreign-born population origin-
ating from intermediate and high HBV endemicity coun-
tries residing in the 31 countries of the EU/EEA; 2) to
estimate the relative contribution of migrants to the
overall burden of CHB in Europe; and 3) to identify the
migrant groups among whom the largest number of
cases are found so as to help direct more effective
screening programmes. In a sister paper (INFD-D-17-
00468) [14], we conduct a similar analysis for chronic
hepatitis C among migrants from endemic countries.
Methods
The data retrieval and analysis process are described in
detail below and in a schematic representation (Fig. 1).
To estimate the number of CHB cases among migrants
in each EU/EEA country, demographic data on the num-
ber of foreign-born migrants by country of birth living,
in EU/EEA countries were extracted from statistical da-
tabases. Country of birth-specific and EU/EEA country-
specific general population Hepatitis B surface antigen
(HBsAg) prevalence estimates were derived from a sys-
tematic literature search (Part 1). To assess the reliability
of using country of birth-derived HBsAg prevalence as a
proxy for the prevalence among migrants, a systematic
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Fig. 1 Schematic representation of the methodological process to estimating the burden of chronic hepatitis B among migrants in the EU/EEA
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literature search was conducted to identify prevalence
estimates among migrants in Europe and to compare
these with country of birth-derived prevalence (Part 2).
Definitions
Migrant (foreign-born population): includes all persons
who were born outside their current country of resi-
dence (and listed in the demographic registration data-
bases used in this study). This includes within-EU/EEA
migrants, i.e. persons born in another EU/EEA country,
as well as those born outside the EU. It does not include
undocumented migrants.
Chronic hepatitis B (CHB): refers to a positive hepa-
titis B surface antigen (HBsAg) test Note: According to
the WHO and EU (2012) case definition, detection of
HBsAg on two occasions at least 6 months apart is clas-
sified as CHB. In this study, as in the seroprevalence and
screening studies from which prevalence data for this
study were extracted, the presence of HBsAg is taken as
the standard proxy for chronic infection. The lack of
regular screening for HBV and the reduction in inci-
dence of acute HBV infections in most countries justify
the assumption that the overwhelming majority of
HBsAg positive cases are chronic.
Hepatitis B endemic country: countries with a ≥ 2%
HBsAg prevalence in the general population. This
follows from the WHO classification of low (<2%),
intermediate (2% to 8%) and high (>8%) endemic
countries.
Part 1: The contribution of migrants from endemic
countries to the burden of CHB in the EU/EEA
Demographic data
The size and country of birth of the foreign-born mi-
grant population was obtained for the 31 EU/EEA coun-
tries from Eurostat for 2013, if available [15]. Where
Eurostat data by country of birth were missing (Croatia,
Cyprus, France, Germany, Malta, Portugal and the UK),
data from the EU 2011 – Housing and Population
Census were used [16]. The most recent demographic
data for Greece (2012) and Luxembourg (2010) were
only available from the Organisation for Economic Co--
operation and Development’ (OECD) Stats website [17].
No demographic data were available from the above
sources for Lithuania. Data were thus obtained from the
Lithuanian National Statistics Service (2013) [18]. The
data source is indicated in footnotes in Table 1. For each
EU/EEA country, the countries of birth of foreign-born
migrants were arranged in descending order of magni-
tude by the number of migrants. The top 50 countries of
birth by size of migrant population were selected for es-
timating the CHB burden.
Systematic literature search to estimate country- specific
HBsAg prevalence
The online databases Medline, Embase, the Cochrane li-
brary, Web of Science, Scopus, PubMed publisher and
Google Scholar were searched in January 2015 for re-
views, systematic reviews and meta-analyses in English
about the prevalence of hepatitis B in the general popu-
lation at national level. The search terms (described in
full in Annex 1 of the Additional file 1) consisted of a
combination of disease-related (hepatitis B), outcome-
related (prevalence), population-related (general popula-
tion, worldwide), and study design-related (reviews)
terms. Since the aim was to identify recent reviews, the
search was restricted to papers published between 2009
and 2014. The titles and abstracts of retrieved articles
were assessed for relevance using exclusion criteria. Key
exclusion criteria included studies about hepatitis other
than type B; focusing on natural history, clinical features
or complications of hepatitis; about medical treatment;
focusing on high risk groups e.g. people who inject
drugs; and single case studies and cost effectiveness ana-
lyses. Full texts of the selected abstracts were retrieved
and assessed, decisions to exclude were recorded and a
PRISMA flowchart (described in Annex 2 of the
Additional file 1) was prepared.
From included reviews, country-specific HBsAg preva-
lence estimates and confidence intervals (CI) were ex-
tracted into a Microsoft Excel database. Where a
country-specific estimate was unavailable, the relevant
Global Burden of Disease region estimate was used, if
available. If a meta-analysis reported a statistically sig-
nificant time trend, the estimate from the most recent
period was selected. When multiple estimates for a
country were available from different reviews, the most
robust or relevant review was selected based on the fol-
lowing criteria: sampling method; representativeness of
population studied; geographical coverage; sample size;
quality of included studies and data collection time-
frame. Decisions were made jointly by two reviewers
(AF and IV) with the rationale recorded for each deci-
sion about a chosen estimate. This rationale, together
with the search strategy, the inclusion and exclusion
criteria and the PRISMA flowchart are described in
annexs 1, 2, 3 and 5 of the Additional file 1 to this article.
Estimating the number of CHB cases among foreign-born
migrants from endemic countries in each EU/EEA country
The retrieved HBsAg general population prevalence esti-
mate in the countries of origin were multiplied by the
number of migrants from that respective country in each
EU/EEA country. The number of migrants born in en-
demic countries (≥2%) was summed to determine the
total and proportional contribution of migrants from
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intermediate/high hepatitis B endemicity countries to
the overall number of migrants residing in the host
country. The ten migrant populations originating from
intermediate and high endemicity countries with the
highest number of HBsAg infected cases in the EU/EEA
were determined.
Relative contribution
To estimate the relative contribution of migrants born
in endemic countries to the overall number of people in-
fected with CHB in the respective EU host country, the
estimated number of infected cases among migrants was
divided by the number of infected persons in that coun-
try based on the general population prevalence. Given
the uncertainty in the size of migrant population and
the CHB prevalence estimates in the countries of
birth, the range of the relative contribution with a
lower and a higher limit was calculated using the
Delta method [19].
EU/EEA-level estimates
The population of the EU/EEA was derived by summing
up the population of all 31 EU/EEA countries as ex-
tracted from demographic sources. To estimate the
HBsAg prevalence in the EU/EEA, the number of esti-
mated HBsAg positive cases in all 31 EU/EEA countries
was summed up and divided by the total EU/EEA popu-
lation. To derive the lower and upper prevalence range,
the lower and upper estimates of the number of cases
across the 31 countries were summed up. To estimate
the number of cases among migrants to and within the
EU/EEA, the number of cases among migrants from en-
demic countries (≥2%) across all 31 countries was
summed up. This was then divided by the number of
cases in the EU/EEA to derive the relative contribution
of migrants from endemic countries to the burden of
CHB infection in the EU/EEA.
Part 2: Systematic literature search for HBsAg prevalence
in migrant populations in Europe
The online databases Medline, Embase, the Cochrane li-
brary, Web of Science, Scopus, PubMed publisher and
Google Scholar were searched in November 2014 for
studies in English that estimate the prevalence of
hepatitis B among migrants in any of the 31 EU/EEA
countries. The search consisted of a combination of
disease-related (hepatitis B), outcome-related (preva-
lence), population-related (migrants) and geographical
area (EU/EEA countries) terms and was limited to stud-
ies published between 2000 and 2014. Only studies
about the prevalence in migrants who were considered
to be representative of the general migrant population
(i.e. not refugees or asylum seekers, hospital patients or
other higher risk groups and not lower risk groups like
pregnant women or children) were compared with in-
country of birth derived prevalence estimates. The full
search strategy, inclusion and exclusion criteria and
PRISMA flowchart can be found in annexs 3, 4 and 6 of
the Additional file 1.
Country-level HBsAg prevalence estimates among mi-
grants residing in different European countries were ex-
tracted from the included studies and entered into
Microsoft Excel. Pooled estimates for countries of birth
were produced by combining the numbers tested and
the number of cases. A 95% CI was re-calculated using
the Fisher’s exact method. Both pooled and large single
study (>25 subjects from a single country of birth) esti-
mates were compared with the in-country estimates ex-
tracted in Part 1 to determine whether in-country
estimates reflect the prevalence found in migrants.
When the point estimate from a study in migrants (Part
2) fell within the CI of the in-country estimate (from
Part 1), the estimate was considered to be comparable;
when it fell below the lower CI limit, it was considered
lower than the in-country prevalence; and when it was
higher than the upper CI limit the prevalence in mi-
grants was considered to be higher.
Results
Estimated CHB prevalence and number of infected cases
in 31 EU/EEA countries
Chronic hepatitis B (HBsAg) prevalence differs consider-
ably among EU/EEA countries, ranging from 0.1% in
Ireland and the Netherlands to 5.5% in Romania. The
average prevalence in the general population of the EU/
EEA is estimated at 1.1%, corresponding to an estimated
5.7 million cases (range 4.0 to 7.5 million). These esti-
mates, together with the total number of infected cases,
are listed in Table 1. Italy and Romania are the EU/EEA
countries with the highest estimated number of CHB
cases, both above 1 million.
The distribution of migrants in the EU/EEA based on HBV
endemicity in country of birth
The top 50 foreign-born populations in each EU/EEA
country included in our analysis make up at least 95% of
the total migrant population in 19 of 31 EU/EEA coun-
tries and at least 90% in all but three EU/EEA countries
(Denmark, Sweden and the UK where it is at least 85%).
These migrant populations account for approximately
9.5% of the population in the EU/EEA. The proportion,
however, ranges from 0.9% in Romania and 1.3% in
Bulgaria to more than 40% in Luxembourg and 62% in
Liechtenstein (Fig. 2). Just over half of the EU/EEA mi-
grant population were born in HBV endemic (≥2%
prevalence) countries. EU/EEA countries with the high-
est proportion of migrants from endemic countries
among their foreign-born population are Croatia,
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Estonia and Latvia (>90%), and those with the lowest
proportion are Liechtenstein, Luxembourg and Slovakia
(<16%) (Fig. 2). The foreign-born population and the
number and proportion from endemic countries in the
EU/EEA and by country are shown in Table 2.
Country-specific HBsAg prevalence estimates
The most comprehensive systematic global review of
country-specific prevalence in the general population
identified by the systematic literature search was a re-
view by Kowdley et al. published in 2012 [20]. This
Table 1 Chronic hepatitis B prevalence in the general population of 31 EU/EEA countries and the estimated number of infected cases
Country Total
Population
HBsAg prevalence Estimated no. of CHB cases
% Low 95% CI High
95% CI
Central estimate Lower estimate Upper estimate
Austria 8,451,149 0.55 0.34 0.71 46,481 28,734 60,003
Belgium 11,161,642 0.7 0.4 1.2 78,131 44,647 133,940
Bulgaria 7,284,552 4.25 2.80 5.70 309,593 203,967 415,219
Croatia 4284,889a 1.47 0.84 2.10 62,988 35,993 89,983
Cyprus 840,407a 0.9 0.3 2 7564 2521 16,808
Czech Republic 10,516,125 0.70 0.43 0.98 73,613 45,219 103,058
Denmark 5,602,628 0.55 0.34 0.71 30,814 19,049 39,779
Estonia 1,320,174 0.58 0.42 0.74 7657 5545 9769
Finland 5,426,674 0.2 0.1 0.4 10,853 5427 21,707
France 64,932,339a 0.68 0.44 1.05 441,540 285,702 681,790
Germany 80,219,695a 0.6 0.4 0.8 481,318 320,879 641,758
Greece 11,090,000b 2.33 1.54 3.11 258,397 170,786 344,899
Hungary 9,908,798 1.08 0.04 2.11 107,015 3964 209,076
Iceland 321,857 0.55 0.34 0.71 1770 1094 2285
Ireland 4591,087 0.1 0 0.3 4591 0 13,773
Italy 59,685,227 1.89 1.26 2.52 1,128,051 752,034 1,504,068
Latvia 2,023,825 1.39 1.10 1.67 28,131 22,262 33,798
Liechtenstein 36,838 0.55 0.34 0.71 203 125 262
Lithuania 2,971,905 d 2.03 1.37 2.69 60,330 40,715 79,944
Luxembourg 506,953c 0.55 0.34 0.71 2788 1724 3599
Malta 417,432 0.55 0.34 0.71 2296 1419 2964
Netherlands 16,779,575 0.1 0 0.2 16,780 0 33,559
Norway 5,049,223 0.55 0.34 0.71 27,771 17,167 35,849
Poland 38,533,299 1.44 1.16 1.72 554,880 446,986 662,773
Portugal 10,562,178a 1.35 0.66 2.04 142,589 69,710 215,468
Romania 20,020,074 5.49 5.24 5.73 1,099,102 1,049,052 1,147,150
Slovakia 5,410,836 0.70 0.43 0.98 37,876 23,267 53,026
Slovenia 2,058,821 3.29 2.33 4.24 67,735 47,971 87,294
Spain 46,727,890 0.66 0.34 0.97 308,404 158,875 453,261
Sweden 9,555,893 0.2 0.1 0.4 19,112 9556 38,224
United Kingdom 63,182,180a 0.54 0.30 0.60 341,184 189,547 379,093
EU/EEAe 509,474,165 1.12 0.79e 1.47e 5,705,260 4,003,937 7,514,179
*Source is EUROSTAT 2013 unless indicated by the following symbol:
aESS 2011 Census
bOECD 2012
cOECDC 2010
dhttp:///www.euras.lt (Lithuanian National Statistics Agency
eFor the 31 EU/EEA countries the cumulative HBsAg prevalence and the upper and lower CI were estimated from the sum of the estimated number of CHB cases
(central, lower and upper estimate), hence these should be considered as upper and lower prevalence ranges and not CI
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provided CHB prevalence estimates for 102 countries,
based on studies published between 1980 and July 2010
using population-based surveys and studies of groups
considered representative of the general population, such
as pregnant women, school children, military recruits
and healthy controls from cohort studies. Studies in emi-
grants to the United States, Europe, Australia and else-
where were also included. Studies in blood donors and
in higher risk populations were excluded. The Kowdley
et al. review used meta-analytic methods to estimate
country- and region-specific pooled HBsAg seropreva-
lence and corresponding 95% CI [20].
Since the Kowdley review did not include a prevalence
estimate for the United States, this was taken from the
most recent nationally representative survey in 2011
[21]. For 11 countries (China, Egypt, Ethiopia, Greece,
Italy, Romania, Saudi Arabia, South Korea, Spain,
Thailand and Turkey), Kowdley [20] reported a statisti-
cally significant decrease in prevalence over time and
therefore the post-2000 estimate was taken. Estimates
from other studies were considered more robust or rele-
vant than this review for 11 countries (Albania, Algeria,
Belgium, Cyprus, Finland, Ireland, Libya, Morocco, the
Netherlands, Sweden and Tunisia) [9, 11, 22], and the
reasons for this are listed in annex 7 of the Additional
file 1. For the 44 countries and territories where no
country estimate was available, the relevant regional esti-
mate calculated by Kowdley was used. All country-
specific prevalence estimates used can be seen in annex 8
of the Additional file 1, to this article.
Estimated prevalence and number of CHB infections
among migrants
In the EU/EEA overall, between 1 million and 1.9
million migrants born in endemic countries are esti-
mated to have CHB infection, which corresponds to an
estimated prevalence of 5.5%. The estimated cumulative
number and range of CHB cases among the top 50
migrant populations from intermediate and high endem-
icity countries in each EU/EEA country is listed in Table
2. The average HBsAg prevalence among migrants from
intermediate and high endemicity countries is also avail-
able for each EU/EEA country, and ranges from 3% in
Estonia, Latvia, Lithuania and Poland to 9% in Portugal.
Migrants originating from China and Romania con-
tribute the largest number of infections, with over
100,000 CHB cases each, followed by migrants from
Turkey, Albania and Russia, in descending order, with
over 50,000 CHB cases each. Table 3 lists the ten mi-
grant populations with the highest estimated number of
CHB cases, adding up to over 680,000 cases and corre-
sponding to 48% of CHB cases among migrants from
endemic countries in the EU/EEA. Table 3 lists the EU
host countries with the largest populations of migrants
born in these countries. Estimates for the 50 migrant
Fig. 2 Total (%) of foreign born population (blue dots) in each EU/EEA country and of those the proportion originating from HBsAg endemic
countries (≥2%)
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groups in each EU/EEA country can be found in annex 9
of the Additional file 1 to this article.
Migrants from China, Romania and Russia are among
the top ten migrant populations with the highest estimated
number of CHB cases in 28, 19 and 18 respectively of the
31 EU/EEA countries as listed in Table 4.
At least three of the ten migrant populations most
affected by CHB in the Czech Republic, Denmark,
Table 2 Foreign-born population and proportion of foreign-born population (from endemic (HBsAg ≥2%) countries), residing in the 31
EU/EEA host countries and the estimated number and range of CHB cases among migrants in these countries as well as the estimated
relative contribution to the total number of cases in the EU/EEA host country
Country Population of foreign-born migrants Foreign-born migrants from endemic countries
Number
from top
50
countries
Number
from HBV
endemic
countries
Proportion
from HBV
endemic
countries
Estimated number of CHB cases Average
CHB
prevalence
Estimated relative
contribution
(and range) of CHB
cases among migrants
to the total number of
CHB cases in the host
country
Central estimate Lower estimate Upper estimate
Austria 1,298,945 768,773 9.1% 33,456 25,757 41,040 4.4% 72% (43% - >100%a)
Belgium 1,596,848 622,206 5.6% 42,530 32,218 54,309 6.8% 54% (20% - 89%)
Bulgaria 90,990 62,755 0.9% 2436 1860 3039 3.9% 1% (0% - 1%)
Croatia 582,271 523,470 12.2% 18,673 11,966 25,376 3.6% 30% (13% - 46%)
Cyprus 190,568 139,689 16.6% 6770 5141 8445 4.8% 90% (2% - >100%a)
Czech Republic 374,296 234,291 2.2% 12,185 9637 14,752 5.2% 17% (9% - 24%)
Denmark 484,139 224,384 4.0% 12,352 9605 15,152 5.5% 40% (24% - 56%)
Estonia 197,744 184,642 14.0% 5432 3822 7038 2.9% 71% (42% - 100%)
Finland 257,044 141,953 2.6% 8136 6206 10,067 5.7% 75% (16% - >100%a)
France 6,775,948 3,591,002 5.5% 212,538 131,238 380,923 5.9% 48% (13% - 84%)
Germany 10,426,860 5,398,700 6.7% 234,792 180,867 288,066 4.3% 49% (29% - 68%)
Greece 713,471 615,986 5.6% 43,163 36,636 49,346 7.0% 17% (11% - 23%)
Hungary 411,403 302,781 3.1% 15,286 13,649 16,940 5.0% 14% (1% - 28%)
Iceland 32,910 7857 2.4% 421 349 494 5.4% 24% (15% - 33%)
Ireland 687,462 205,071 4.5% 13,196 10,935 15,574 6.4% >100% (<0% - >100%a)
Italy 5,319,754 3,443,409 5.8% 213,063 174,632 251,539 6.2% 19% (12% - 26%)
Latvia 278,243 267,617 13.2% 7866 5269 10,454 2.9% 28% (17% - 39%)
Liechtenstein 22,806 2140 5.8% 97 74 119 4.5% 48% (28% - 67%)
Lithuania 139,712 121,992 4.1% 3765 2469 5057 3.1% 6% (3% - 9%)
Luxembourg 189,858 28,085 5.5% 1450 913 2019 5.2% 52% (26% - 78%)
Malta 33,301 9629 2.3% 637 429 860 6.6% 28% (15% - 41%)
Netherlands 1,772,756 1,052,695 6.3% 56,650 40,335 73,016 5.4% >100% (<0% - >100%a)
Norway 597,316 277,047 5.5% 17,021 12,125 21,979 6.1% 61% (34% - 88%)
Poland 659,657 438,446 1.1% 11,679 7018 16,342 2.7% 2% (1% - 3%)
Portugal 854,830 475,155 4.5% 42,688 29,595 55,795 9.0% 30% (12% - 48%)
Romania 166,973 103,740 0.5% 7531 5453 9581 7.3% 1% (0% - 1%)
Slovakia 155,346 25,170 0.5% 1073 846 1301 4.3% 3% (2% - 4%)
Slovenia 231,276 160,220 7.8% 5713 3756 7663 3.6% 8% (5% - 12%)
Spain 5,930,170 1,909,343 4.1% 118,316 92,282 148,318 6.2% 38% (18% - 59%)
Sweden 1,304,130 596,303 6.2% 33,850 23,728 44,011 5.7% >100% (34% - >100%a)
United Kingdom 6,845,805 3,976,870 6.3% 244,409 195,342 294,417 6.1% 72% (47% - 96%)
EU/EEA 48,622,832 25.911.421 5.1% 1,427,174 1,074,152 1,873,032 5.5% 25% (15% - 35%)
aThe Delta method does not give a reliable confidence interval around the relative contribution as the relative contribution is close to 100% and the distribution
of cases in the general population is extremely skewed
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Finland, Hungary, Iceland, Liechtenstein, Norway, the
Netherlands and Sweden were born in South-East or
East Asian countries including China, Vietnam, the
Philippines and Thailand. People born in Yugoslavia be-
fore 1992 or in one of the former Yugoslav Republics
since 1992 are represented among three or more of the
top ten migrant populations with the highest number of
infected cases in Austria, Liechtenstein and Luxembourg
as well as in Croatia and Slovenia. Similarly, people born
in the Soviet Union before 1991 or in one of the former
Soviet Republics since 1991 are represented among three
or more of the top ten migrant populations most af-
fected by CHB in Bulgaria, Cyprus, the Czech Republic,
Germany, Hungary, Poland, Romania and Slovenia as
well as in the Baltic states of Estonia, Latvia and
Lithuania (see annex 9 of the Additional file 1).
In the UK, migrants from India, Pakistan and
Bangladesh are among the top ten migrant populations
with the highest number of infected cases. Migrants
from Maghreb countries such as Algeria and Tunisia are
represented in the top ten in France. Across the EU/
EEA, African countries of origin that contribute a large
number of estimated cases include Eritrea, Ghana,
Nigeria, Senegal, Somalia and South Africa. In Belgium,
France, Luxembourg, Malta, Portugal and the UK, four
or more of the ten migrant populations most affected by
CHB are from African countries.
Relative contribution of migrants from endemic countries
to the overall CHB burden in EU/EEA countries
The relative proportion of infected migrants from
endemic countries among the overall number of CHB
Table 3 The ten migrant groups (from HBsAg endemic countries) with the highest estimated number of CHB cases (rounded) and
the main host EU/EEA countries
Migrant country of
origin
Total migrant population in
Europe
HBsAg
prevalence
Cumulative number of CHB
cases
Host countries (first 6 with largest populations)a
Romania 2,817,458 5.5 154,679 Italy, Spain, Germany, Hungary, UK, Austria
China 1,012,550 10.2 103,585 UK, Italy, Spain, France, Germany, Netherlands
Turkey 2,266,977 4.3 97,255 Germany, France, Netherlands, Austria, Belgium,
UK
Albania 804,570 9.0 72,412 Italy, Greece, Belgium, Austria, Bulgaria
Russia 1,810,197 2.9 52,315 Germany, Latvia, Estonia, Italy, Spain, Lithuania
Vietnam 365,048 12.5 45,557 France, Germany, Czech Republic, UK, Sweden,
Norway
Nigeria 336,155 13.3 44,741 UK, Italy, Spain, Ireland, Netherlands, Austria
Kazakhstan 828,526 5.0 41,013 Germany, Latvia, Czech Republic, Poland,
Lithuania, Estonia
Algeria 1,482,465 2.6 38,544 France, Spain, Belgium, Italy, Ireland
India 1,120,352 3.2 36.188 UK, Italy, Germany, France, Spain, Ireland
Total 686,289b
aif migrant population is at least 1000
bThe sum of CHB cases among the ten migrant groups with the largest number of CHB cases (686,289) corresponds to 48% of the total number of CHB cases
among migrants from endemic countries (1,427,174)
Table 4 Countries of birth of foreign-born migrants found
amongst the ten migrant groups most affected by chronic
hepatitis B in 10 or more of the 31 EU/EEA countriesa
Country of
birth of
migrants
Number of
EU/EEA countries
(of 31)
EU/EEA Countries
China 28 AUT, BEL, BLG, HR, CZ, DK, DE, FIN, FR,
EE, HU, IRL, ISL, IT, LIE, LT, LUX, MT, NL,
NO, PL, PT, RO, SK, SI, ES, SE, UK
Romania 19 AUT, BEL, BLG, HR, CY, CZ, DK, DE,
GRC, HU, IRL, ISL, IT, LUX, MT, PL, PT,
SK, ES,
Russia 18 AT, BLG, HR, CY, CZ, DE, FIN, EE, GRC,
HU, ISL, LT, LV, MT, PL, RO, SK, SI
Ukraine 14 BLG, HR, CZ, DE, EE, HU, IT, LT, LV, PL,
PT, RO, SK, SI
Vietnam 14 BLG, CY, CZ, DK, DE, FIN, FR, HU, ISL,
NL, NO, PL, SK, SE
Turkey 12 AUT, BEL, BLG, DK, DE, FIN, FR, GRC,
LIE, NL, RO, SE
Moldova 11 BLG, CY, CZ, EE, IRL, IT, LT, LV, PT,
RO, SI
Philippines 11 AUT, CY, DK, GRC, IRL, ISL, IT, MT, NO,
ES, UK
Afghanistan 10 AUT, BEL, DK, DE, FIN, HU, NL, NO,
SK, SE
Bosnia and
Herzegovina
10 AUT, HR, DK, DE, LIE, LUX, NO, PL,
SI, SE
aselected from the ten largest CHB affected migrant groups from
intermediate/high endemicity countries in the EU/EEA countries
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cases in EU/EEA countries is shown in Table 2 and
Fig. 3. Migrants from intermediate and high endemicity
countries contribute more than 90% and, in some in-
stances, up to 100% of the total estimated number of
CHB cases in Cyprus, Ireland, the Netherlands and
Sweden. Conversely, in Bulgaria, Poland, Romania and
Slovakia, migrants contribute less than 4% of the total.
Comparing migrant-derived HBsAg prevalence with country
of origin estimates
Sixteen HBsAg prevalence studies in migrants residing
in Europe were identified from the literature search for
comparison with the in-country estimates derived in
Part 1 (Table 5). Prevalence figures for migrants from
Suriname and the Dutch Antilles could only be com-
pared with a regional estimate, since in-country data
were not available from the review studies in Part 1.
In nine of the remaining 14 studies in migrants,
HBsAg prevalence figures were lower than the derived
in-country estimate. Prevalence among migrants was
comparable with the in-country or region estimate for
four migrant populations. HBsAg prevalence among
migrants from Albania was higher than the in-
country estimate.
Discussion
The number of CHB cases in the general population of
the 31 EU/EEA countries is estimated at between 4
million and 7.5 million cases, with a disproportionately
high number of these cases found among migrants.
Although migrants from endemic countries make up only
one in 20 EU/EEA citizens, they account for one in four
of all CHB infections. Migrants from ten countries
account for 48% of all CHB cases among migrants in the
EU/EEA.
The data suggest that the relative contribution of mi-
grants to the overall CHB burden is higher in Western
and Northern European countries than in Southern and
Eastern European countries. The relative contribution of
migrants to the overall burden of CHB is lowest (<4%)
in EU/EEA countries with a higher HBsAg prevalence
and a lower proportion of migrants such as Romania,
Bulgaria, Slovakia and Poland. Conversely, the relative
contribution is very high (>100%) in EU/EEA countries
with a very low HBsAg prevalence such as Ireland, the
Netherlands and Sweden. The estimate of over 100% is a
result of the prevalence in the general population of the
host country likely to be underestimated (because mi-
grants and other higher risk, harder to reach populations
are underrepresented in the samples used to determine
this prevalence) or because the prevalence in countries
of birth of migrants is an over-estimation of the actual
prevalence among migrants.
To assess whether the country of birth prevalence esti-
mates used are over-estimates, we compared these esti-
mates to the prevalence reported in migrant studies in
Europe and found evidence indicating an over-
estimation. Based on the epidemiologic features of HBV,
the lower than in-country prevalence among migrants
from 9 of 14 countries was surprising, since the infection
is often acquired at birth or in early childhood in coun-
tries where HBV is endemic. One explanation could be
an age or cohort effect, since the estimates of in-country
prevalence include older data from the 1980s and 1990s,
while most of the migrant studies in Europe used for
comparison were conducted after 2000. A recent study
estimating hepatitis B prevalence by region showed a de-
crease in most regions between 1990 and 2005 [6]. This
decrease is largely explained by the widespread introduc-
tion of antenatal HBV screening together with risk group
and infant HBV vaccination programmes [23] and the
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resulting decline in incidence. The healthy migrant ef-
fect, the hypothesis that migrants are often younger and
healthier than the general population in their countries
of birth, may also be a factor [24]. Study design should
also be considered. The figures for prevalence among
migrants living in EU/EEA countries tend to be based on
data from small-scale, local studies that mostly use con-
venience sampling, such as screening studies (Table 5).
These may under-estimate the true prevalence because
people who have already been diagnosed may not partici-
pate. Nevertheless, although prevalence among migrants
from intermediate and high endemicity countries may not
be as high as in the country of birth, the evidence strongly
suggests that it is still considerably higher than among the
host population in EU/EEA countries and high enough for
screening of affected migrant groups to be cost-effective
[11, 25].
This study seeks to inform national screening efforts.
The results suggests that an approach focused solely on
migrants would have limited impact in most Eastern
European countries, specifically Bulgaria, Lithuania,
Poland, Romania, Slovakia and Slovenia, where the rela-
tive contribution of migrants to the overall national bur-
den of CHB is low (between 1% and 8%) and the
proportion of migrants from endemic countries is also
low (<5%). In addition, Bulgaria, Lithuania, Romania and
Slovenia are HBV-endemic countries with an HBsAg
prevalence of >2.0% to 5.5%. A more effective approach
would be to screen sub-groups of the general popula-
tion, i.e. birth cohorts born before antenatal screening,
childhood HBV vaccination and the regular screening of
blood/blood products were introduced. Screening indi-
viduals potentially exposed to HBV through transfu-
sions, transplants and dental or surgical procedures may
also help to identify cases.
In contrast, targeted migrant screening approaches
would be of value in countries such as Austria, Cyprus,
Estonia, Finland, Ireland, the Netherlands, Sweden and
UK, where more than 70% of CHB cases are estimated
to be among migrants from endemic countries. To opti-
mise cost-effectiveness, screening should target those
migrant populations that are most at risk of chronic viral
hepatitis infection where the likelihood of detecting
cases is higher.
Screening and subsequent contact tracing increases
the diagnosis rate and, together with effective linkage to
and retention in care and antiviral treatment, are the key
to effective secondary prevention. The asymptomatic na-
ture of the disease until its late stages and the lack of
awareness of risk among migrants and often also among
health care providers limit early detection. Other bar-
riers to screening include language, health care access
Table 5 HBsAg prevalence derived from studies among general migrant populations resident in Europe compared to in-country
prevalence estimates derived from worldwide systematic reviews
Country Migrants In-country of origin Comparison
N tested Prevalence 95% CI Reference Prevalence 95% CI Reference
Afghanistan 293 2.1 0.8–4.4 [30] 10.5 5.9–15.1 [20] Lower
Albania 504a 11.7 9.0–14.8 [31] 9.0 8.1–9.8 [9] Higher
Bangladesh 934 1.3 0.7–2.2 [32, 33] 4.8 4.0–5.6 [20] Lower
Chinab 1319 9.4 7.9–11.1 [33, 34] 10.2 c 9.4–11.2 [20] Comparable
Dutch Antilles 38 2.6 0.1–13.8 [35] 4.5d 2.5–6.6 [20] Comparable
Egypt 465 1.1 0.4–2.5 [36] 4.2 c 1.9–6.5 [20] Lower
Former USSR 675 4.7 3.3–6.6 [30, 37] 3.8 2.7–4.9 [20] Comparable
India 1334 0.1 0–0.4 [32, 38] 3.2 2.9–3.6 [20] Lower
Iran 153 0.7 0.1–2.5 [30] 3.1 2.7–3.5 [20] Lower
Iraq 290 0.7 0–3.6 [30] 1.3 0–2.9 [20] Comparable
Morocco 305 0.3 0–1.8 [35, 39] 1.8 1.5–5.9 [20, 22] Lower
Pakistan 3786 1.6 1.2–2.1 [32, 33, 38, 40] 4.2 3.6–4.8 [20] Lower
Somalia 317 7.3 4.6–10.7 [41] 12.4 8.9–15.9 [20] Lower
Suriname 56 0 0–6.4 [35] 4.5d 2.5–6.6 [20] Lower
Turkey 902 3.7 2.5–5.1 [30, 35, 39] 4.3c 3.7–4.9 [20] Comparable
Vietnam 149 10.7 6.3–16.9 [30, 33] 12.5 11.5–13.5 [20] Lower
Notes:
aage range of participants 10–23 years
bincluding Hong Kong
cstatistically significant decline over time reported therefore the latest estimate (from year 2000 onwards) selected
dregional estimate for Caribbean only
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and entitlement issues, high work-load among health
care staff, and the potential stigma or fear associated
with being diagnosed positive [26, 27]. The EU-funded
HEPscreen project describes four different screening ap-
proaches: (i) outreach screening (e.g. through awareness
raising and screening sessions in communities or work-
places); (ii) extension of existing screening programmes
(e.g. expanding tuberculosis screening to include other
diseases); (iii) opportunistic screening (e.g. offering viral
hepatitis screening when patients attend for other health
care services); and (iv) invitation-based screening (e.g.
using municipal or general practice registers). Summar-
ies of screening studies conducted using these different
methods, practical guides on how to implement different
screening approaches among migrants and resource and
logistical considerations are available on the website
http://www.hepscreen.eu/ and present a useful resource
for public health practitioners [28].
Undocumented migrants are also an important and
vulnerable group. Lack of robust demographic data and
the diversity in size and country of birth of undocu-
mented migrants [29] hinder effective planning, resour-
cing and evaluation of screening interventions for this
population. In addition, undocumented migrants face
specific access and entitlement challenges when acces-
sing public health services. Promoting voluntary screen-
ing for this vulnerable group would have public health
benefits, but would require national policies that allow
undocumented migrants to receive treatment without
adverse consequences.
The systematic approach to estimation of the burden
of CHB among migrant populations in the EU/EEA
overall and in each of the 31 EU/EEA countries is a
strength of this study. The data that underpin these esti-
mates are derived from a common demographic data
source (Eurostat 2013) for most countries and from pub-
lished meta-analytic studies. A potential limitation is
that, for some countries, demographic data from earlier
years and other sources had to be used. In addition,
there are differences in population registration and
reporting systems between EU/EEA countries. However,
using data from 2013 or earlier has the advantage of lim-
iting the effect of reporting delays with respect to accur-
ate numbers of migrants and their countries of birth.
Using country of birth prevalence data to estimate the
CHB burden among migrants may have resulted in a de-
gree of over-estimation for some countries, because of
differences in the age structure, risk profile and socio-
economic status between different migrant groups.
Migrants sharing the same country of birth but residing
in different EU/EEA countries may also differ in terms
of risk profile as a result of differences in host country
pull factors and reasons for migration. Data allowing a
comparison of prevalence figures between the general
population in the migrants’ countries of birth and from
studies among migrants in Europe were however only
available for 14 countries. An additional strength of this
study is that, even if the absolute number of estimated
CHB cases lies closer to the lower estimate, it identifies
which migrant populations would benefit most from tar-
geted screening programs and linkage to care.
Conclusions
Today, anti-viral treatments for CHB can benefit most
patients, offering the prospect of significant public
health gains through secondary prevention. Expanded
access to screening, linkage to care and treatment,
together with the continued implementation of existing
primary prevention measures such as vaccinaiton and
antenatal screening, are the cornerstones of eliminating
viral hepatitis as a global public health threat in the next
few decades.
This study confirms that migrant populations are a
key risk group for CHB in specific EU/EEA countries. It
details the number of CHB cases among migrants by
country of birth in each EU/EEA country, identifies the
migrant populations that would benefit most from
screening and treatment, and highlights which EU/EEA
countries would benefit from a migrant-targeted screen-
ing approach. The findings in this study about which
migrant groups are at highest risk is also useful for
developing linguistically-specific and culturally-sensitive
screening programmes and raising awareness among
physicians so that they offer screening. Efficient and
innovative public health approaches to increase access to
screening and to screen high-risk populations are
needed. Experience from a migrant-specific screening
project conducted at the EU/EEA level [28] can help to
inform the design of screening programmes that can
successfully reach migrant communities. Planners and
practitioners can also use the results presented here and
those from the HEPscreen project to develop evidence-
based screening interventions that target the most
affected migrant populations.
Further research is required to inform the develop-
ment and assessment of effective and cost-effective
screening interventions and long-term patient follow up,
as well as to improve linkage to and retention in treat-
ment and care among hard to reach risk populations, if
we are to realise the vision of a world free of viral
hepatitis.
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Additional file 1: Estimating the scale of chronic hepatitis B virus infection
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criteria of global/worldwide systematic reviews and meta-analyses and the
rationale for the selected country specific hepatitis B and C prevalence
figures. (ii) Annexs 3, 4 and 6 present data on the search strategy, the PRISMA
flow chart and the inclusion and exclusion criteria for chronic hepatitis B/C
prevalence studies among migrants in the EU/EEA. (iii) Annex 8 presents a
list of the country specific HBsAg prevalence estimates selected along with
the corresponding source. (iv) Annex 9 presents country tables which list the
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